arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

MYRIAD GENETICS INC

MYGN
$6.29 ▲ +0.27 (+4.49%) at close
Healthcare ·In Vitro & In Vivo Diagnostic Substances ·USIn Vitro & In Vivo Diagnostic Substances
72 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
19
Health
Poor
Bearish
auto_awesome

Analytical Summary

MYRIAD GENETICS INC faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $596.3M
Dividend Yield —
Revenue Growth -10.5% ↘
Op. Margin -20.4% ↘
ROIC -9.3% ↘
FCF / Share $-0.09 ↗
Trailing P/E —
Price / Book 2.0x
FCF Yield —
Debt / Equity 0.40
info Valuation on last close. End-of-day price, Nov 5, 2026.

72-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$190.70M
↓ -10.5% —
Net Income Profit after all expenses
$-34.10M
↓ -34000.0% —
Operating Margin Operating profit as % of sales
-20.4%
↓ -33.2% 5th
FCF / Share Free cash flow per share
$-0.09
↑ +47.7% —
Long-Term Debt Long-term obligations
$120.70M
— +0.3% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↓
12
Returns ↓
9
Financial Health ↓
40
Cash Quality ↑
22

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 19 years · 72 quarters